This atypical CLL score proposed in this study helped to offer an accurate differentiation of CLL from non‐CLL malignancies, particularly in CD5 or CD23‐negative mature B‐cell neoplasms with a clinical suspicion of CLL. This evidence concerns the gene FCER2 and B-cell chronic lymphocytic leukemia.